Last edition
News about "Antibody-Drug Conjugate "
The first patient has been dosed in the global Phase 3 TROPION-Urothelial04 trial, advancing evaluation of Datroway-based therapies for high-risk muscle-invasive urothelial cancer.
Antibody-Drug Conjugate | 27/08/2026 | By News Bureau
Akeso's B7-H3 ADC AK157D1 Cleared for Phase I Clinical Trial in China
Akeso has received NMPA clinical trial clearance for AK157D1, a next-generation B7-H3-targeting ADC, paving the way for a Phase I study in patients with advanced solid tumours in China.
Antibody-Drug Conjugate | 24/08/2026 | By News Bureau
Akeso Doses First Patient in Phase 1b/2 Trial of HER3 ADC for Advanced Lung Cancer
Akeso has dosed the first patient in its Phase 1b/2 AK138D1-201 trial, assessing the HER3-targeted antibody-drug conjugate AK138D1 as monotherapy and in combination with ivonescimab for patients with advanced non-small cell lung cancer.
Antibody-Drug Conjugate | 30/07/2026 | By News Bureau | 127
AstraZeneca's investigational antibody-drug conjugate Sone-Ve demonstrated a significant overall survival benefit in the Phase 3 CLARITY-Gastric01 trial, marking a milestone in the development of targeted therapies for CLDN18.2-positive advanced gastric cancer.
Antibody-Drug Conjugate | 28/07/2026 | By News Bureau
Bio-Thera Doses First Patient in Phase 1 Trial of CD25-Targeting ADC BAT8013
Bio-Thera Solutions has dosed the first patient in a Phase 1 trial of BAT8013, a novel CD25-targeting antibody-drug conjugate designed to enhance anti-tumour immune responses in patients with advanced solid tumours.
Antibody-Drug Conjugate | 27/07/2026 | By News Bureau | 110
Glenmark Advances Global Phase 3 Trial of HER2-Targeted ADC for Platinum-Resistant Ovarian Cancer
Glenmark Specialty has initiated patient enrolment in India for the Phase 3 trial of trastuzumab rezetecan, aiming to expand treatment options for patients with platinum-resistant ovarian cancer across its licensed global markets.
Antibody-Drug Conjugate | 04/07/2026 | By News Bureau | 125
The European Commission has approved Trodelvy for first-line treatment of unresectable or metastatic triple-negative breast cancer, offering a new therapeutic option for patients with one of the most aggressive forms of breast cancer.
Antibody-Drug Conjugate | 25/06/2026 | By News Bureau | 105
Zai Lab Secures China Approval for TIVDAK
Zai Lab has received China NMPA approval for TIVDAK (tisotumab vedotin), the first Antibody-Drug Conjugate (ADC) approved for previously treated recurrent or metastatic cervical cancer in China. The approval is supported by phase 3 innovaTV 301 trial data demonstrating a statistically significant overall survival benefit.
Antibody Drug Conjugate | 09/06/2026 | By News Bureau | 189
Antengene Corporation receives CDE endorsement to begin pivotal phase 3 CLINCH-3 study of ATG-022
Antengene has received approval from China’s Center for Drug Evaluation to initiate the pivotal Phase 3 CLINCH-3 study of ATG-022, advancing the development of its innovative antibody-drug conjugate for CLDN18.2-positive gastric cancers.
Antibody-Drug Conjugate | 30/05/2026 | By News Bureau | 112
US FDA Approves DECNUPAZ for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
AbbVie has received US FDA approval for DECNUPAZ to treat adults with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), marking the first and only outpatient-initiated ADC for BPDCN and AbbVie’s first approved Antibody Drug Conjugate (ADC) for hematologic malignancies.
Antibody Drug Conjugate | 30/05/2026 | By News Bureau | 125
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy